Assessment of the antifungal susceptibility profile and virulence factors of non-albicans candida species obtained from the infection of the bloodstream
Keywords:
antifungal therapy, susceptibility testing, bloodstream infections, Candida, candidemia, virulence factorAbstract
Background: Earlier the fungal infection spectrum was considered to be only restricted to mucocutaneous and cutaneous tissues. However, this consideration has now changed. The threatening rise in the incidence of invasive mycosis is seen recently. Despite advancements in diagnostic and therapeutic modalities, high mortality rates are linked to invasive mycosis. The most common cause of bloodstream infections is Candida spp. Among candida genus, the most pathogenic species is C. Albicans, recent literature data has shown the emergence of treatment-resistant, relatively uncommon, and unusual nonalbicans Candida (NAC) spp. Aim: The present study was conducted to assess the antifungal susceptibility profile and virulence factors of non-Albicans candida species obtained from the infection of the bloodstream. Material and methods: The present study included blood culture isolates of nonalbicans Candida (NAC) spp. which were identified to species level using the standard mycological protocol. This NAC spp. were screened for virulence factors production including biofilm formation, hemolysin, and extracellular hydrolytic enzymes. Ezy MIC strip was used for assessing the antifungal susceptibility profile of these isolates. Results: 100% (n=1) C. rugosa NAC spp. showed hemolysin production. In C. gulliermondii, 50% (n=1) subject showed phospholipase production and biofilm formation each.
Downloads
References
Aoki S, Ito-Kuwa S, Nakamura Y, Masuhara T. Comparative pathogenicity of a wild-type strain and respiratory mutants of Candida albicans in mice. Zentralblatt Fur Bakteriologie 1990; 273:332-43.
Berkow E, Lockhart S. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237-45.
Branchini M, Pfaller M, Rhine-Chaleberg J, Frempong T, Isenberg H. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994;32:452-6.
Deorukhkar S, Saini S, Mathew S. Non-albicansCandida Infection: An Emerging Threat. Interdisciplinary Perspectives Infectious Diseases 2014;3:6-13
Deorukhkar SC, Roushani S. Fluconazole resistance in Candida species: Ten years experience at a rural tertiary care teaching hospital in India. Journal of Infectious Diseases and Pathogenesis 2017;1:102.
Kathiravan M, Salake A, Chothe A, Dudhe P, Watode R, Mukta A, et al The biology and chemistry of antifungal agents: A review. Bioorg Med Chem 2012;20:5678-98.
Kauffman C. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006;9:483-8.
Kumar V, Latha R, Vedhagiri K, Sathiamoorthi T, Jayarani G, Sasikala R et al. Phospholipase C, proteinase and hemolytic activities of Candida spp. isolated from pulmonary tuberculosis patients. J Mycol Med 2009;19:3-10
Lopez-Martinez R. Candidosis, a new challenge. Clin Dermatol 2010;28:178-84.
Luo G, Samaranayake L, Yau J. Candida species exhibit differential in vitro hemolytic activities". J Clin Microbiol 2001;39:2971-4.
Maertens J. History of the development of azole derivatives. Clin Microbiol Infect 2004;10:1-10.
Mane A, Pawale C, Gaikwad S, Bembalkar S, Risbud A. Adherence to buccal epithelial cells, enzymatic and hemolytic activities of Candida isolates from HIV-infected individuals. Med Mycol 2011;49:548-51.
Samaranayake LP, Raeside JM, MacFarlane TW. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 1984; 22:201-7.
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products, and new therapeutic options. J Med Microbiol 2013;62:10-24.
Silva S, Negri M, Henriques M, Oliveria R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis, and Candida tropicalis biology, epidemiology, pathogenicity, and antifungal resistance. FEMS Microbiol Rev 2012;36:288-305.
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discover Today Technol 2014;11:65-71.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
